StocksEditas Medicine IncEDIT

EDIT

Editas Medicine Inc

11.61 0.50 (4.50%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
11.60
B
11.66

Overview

Prev Close11.61
Day's Range 11.14 - 11.77
52 Week Range 9.70 - 72.92
Average Volume (3m)1.72M
1-Year Return-64.88%
Beta1.5353
Market Cap764.65M
P/E Ratio
Revenue25.82M
EPS-2.7307
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.707/12/202116/02/202228/04/202215.0020.0025.0030.0035.0040.00
Chart times in UTC
Industry Biotechnology
CEO James C. Mullen, MBA
Employees 264

FINANCIAL SUMMARY

For the quarter ended 31/3/2022, Editas Medicine Inc's revenues decreased by 45.70% and amounted to 6.77M. Net income decreased by 21.91% to -50.52M. Net assets decreased by NaN to N/A and EPS decreased from -0.61 to -0.74.
EDIT's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
N/A
Net Profit Margin
-550.73%
Operating Margin
-724.41%
Return On Investment
-39.89%
06/21
09/21
12/21
03/22
Total Revenue
379K
6.2M
12.47M
6.77M
Gross Profit
N/A
N/A
N/A
N/A
Operating Income
-55.4M
-39.25M
-41.61M
-50.75M
Net Income
-55.26M
-39.08M
-41.44M
-50.52M